DAVID G MENTER to Trifluridine
This is a "connection" page, showing publications DAVID G MENTER has written about Trifluridine.
Connection Strength
0.211
-
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2023 02; 41(1):25-34.
Score: 0.211